Skip to main content

Table 5 Clinical trials of MPs-based cancer therapy

From: Microparticles: biogenesis, characteristics and intervention therapy for cancers in preclinical and clinical research

Disease

Drug

MPs source

Phase, n of patients

Objective response rate

Refs.

Malignant Pleural

Effusion

MTX

Autologous tumor cells

Phase 2,

n = 11

90.91%

NCT02657460 [91]

Malignant Pleural

Effusion

Cisplatin

Tumor cells

Phase 2,

n = 6

100%

NCT01854866 [85]

Malignant Pleural

Effusion

MTX

Tumor cells

Phase 2,

n = 32

84.38%

ChiCTR-ICR-15006304 [92]

Cholangiocarcinoma

MTX

Tumor cells

Phase 2,

n = 20

100%

ChiCTR-OIB-15007589 [93]